BioCentury
ARTICLE | Finance

Pays to stay private

Why ADC Therapeutics chose to stay private with $200 million financing

October 26, 2017 10:06 PM UTC

While ADC Therapeutics S.A. has the hallmarks of a biotech ready for the public markets, the Swiss cancer company decided to stay private with its latest financing, citing the relative cost of capital.

The oversubscribed $200 million private placement ADC announced Oct. 23 will help the company advance two compounds into pivotal trials and give it runway through YE19, at which time CEO Chris Martin told BioCentury it will revisit whether an IPO makes sense...

BCIQ Company Profiles

ADC Therapeutics S.A.